In vivo integral feedback control for robust synthetic biology
Lead Research Organisation:
City, University of London
Department Name: School of Social Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Claire Marris (Principal Investigator) |
| Description | Workshop on the Prospects for Controllable Cell-Based Therapies |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop on the prospects for controllable cell-based therapies Organised by Claire Marris, Sociology Department, City University London Guy-Bart Stan, CSynBI, Department of Bioengineering, Imperial College London Karen Polizzi, CSynBI, Department of Life Sciences, Imperial College London Jordan Ang, CSynBI, Department of Bioengineering, Imperial College London feedback control for robust synthetic biology' (grants EP/K020781/1 and EP/K020617/1) This workshop brought together diverse stakeholders to discuss the prospects for an emerging category of medical applications of synthetic biology that we are calling 'controllable cell-based therapies' (CCBTs) including: • scientists conducting cutting-edge research to enable CCBTs • firms seeking to commercialise CCBTs • staff from agencies involved in the regulation of CCBTs • independent experts on regulatory frameworks and translation for CCBTs • staff from patient advocacy groups with expertise in medical innovation and regulation • social scientists with expertise in medical innovation and regulation The workshop provided a unique opportunity for people from these diverse groups to engage with each other in order to identify potential opportunities and challenges for this novel set of medical applications. Questions that were addressed at the workshop included: • What is the current scientific, economic and regulatory landscape for CCBTs? • How do CCBTs compare to alternative approaches to health and medicine? • How can we ensure that these new therapies reach the clinic and provide actual benefits to patients without generating unreasonable risks? • What implications might the use of bacterial (as opposed to human) cells have in terms of safety, regulatory frameworks and other challenges for translation to the clinic? This workshop sought to encourage interactive discussions among people with different expertise and interests. Emphasis was given to group discussion, focused around case-studies. A small number of short presentations from experts from different disciplines helped set the scene and provide participants with basic information about: current cutting-edge science, ongoing commercial developments, regulatory frameworks, Health Technology Assessment, patient perspectives and consumer perspectives. The total number of participants was relatively small (25) in order to facilitate constructive discussions. The Chatham House rule applied whereby "participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed." |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.bg.ic.ac.uk/research/g.stan/group/CCBT_Workshop/CCBT_Workshop.html |